Adherence and recommended optimal treatment to Azvudine application for the treatment of outpatient COVID-19 patients: A real-world retrospective study [PDF]
HeliyonBackground: Azvudine was approved for the treatment of coronavirus disease 2019 (COVID-19) in China and has been widely used since the outbreak in December 2022. However, real-world research on the adherence of Azvudine is lacking.
Zhuoling An
exaly +4 more sources
Advances in the effectiveness and safety of azvudine treatment: a comprehensive review [PDF]
Frontiers in PharmacologyThe global impact of COVID-19 has highlighted the urgent need for effective therapeutic interventions against SARS-CoV-2. Azvudine, a dual-target nucleoside drug initially developed for human immunodeficiency virus (HIV), has gained attention for its ...
Chang Junbiao, Zheyi Dong, Wenge Li
exaly +4 more sources
Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study
Acta Pharmaceutica Sinica B, 2023 In our retrospective cohort study, we aim to explore whether Azvudine modifies the risk of death in COVID-19 patients. It was conducted on the medical records of patients, consecutively admitted for COVID-19 pneumonia to two hospitals in Chongqing, China.
Shiying Li
exaly +3 more sources
Frontiers in Pharmacology, 2023 Azvudine (FNC) is a synthetic nucleoside analog used to treat adult patients living with human immunodeficiency virus-1 (HIV-1) infection with high viral load.
Ke-Wei Zhu
exaly +3 more sources
Heliyon, 2023 Background: Although vaccinations and antiviral drugs are widely used in the clinical treatment worldwide, there is little investigation on the clinical outcomes and effectiveness of oral Azvudine tablets (FNC) treatment in COVID-19 hospitalized patients.
Yanli Zhao
exaly +3 more sources
Real-world data of Azvudine-induced hepatotoxicity among hospitalized COVID-19 patients in China: a retrospective case-control study [PDF]
Frontiers in PharmacologyBackgroundThe COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to global health crisis. Although several antiviral drugs have been used to mitigate the severity and mortality of COVID-19, the safety profile remained a critical concern. Azvudine,
Yuanguo Xiong +8 more
doaj +2 more sources
Impact of early and delayed azvudine administration on COVID-19 mortality: a retrospective study [PDF]
Scientific ReportsAzvudine is recommended for patients with coronavirus disease 19 (COVID-19); however, its optimum therapeutic time window and its impact on mortality of patients are unclear.
Luo Wang +26 more
doaj +2 more sources
Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching [PDF]
Frontiers in Cellular and Infection MicrobiologyBackgroundClinical trials have demonstrated the efficacy of azvudine in alleviating clinical symptoms among patients with coronavirus disease 2019 (COVID-19).
Jing Zhang +5 more
doaj +2 more sources
Frontiers in Pharmacology, 2023 Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment of COVID-19 in China, however, limited real-world data exists regarding their effectiveness and safety.Methods: We conducted a retrospective cohort study involving
An-Hua Wei +7 more
exaly +3 more sources
Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China [PDF]
BMJ OpenObjectives Azvudine and Paxlovid are the primary antiviral agents for the management of COVID-19. However, there is currently insufficient evidence regarding the effectiveness and safety of these drugs in treating COVID-19 patients with pre-existing ...
Ling Wang +14 more
doaj +2 more sources